Article
Oncology
Kurt W. Evans, Erkan Yuca, Stephen S. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio F. Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric-Bernstam
Summary: Oxidative phosphorylation is a metabolic vulnerability in triple-negative breast cancer, and inhibiting it with IACS-10759 may enhance efficacy of multiple targeted therapies.
Article
Oncology
Zahi Mitri, Nour Abuhadra, Shaun M. Goodyear, Evthokia A. Hobbs, Andy Kaempf, Alastair M. Thompson, Stacy L. Moulder
Summary: By applying an Evolutionary Action Score (EAp53) to functionally characterize TP53 mutations in TNBC patients, this study found that EAp53 stratification may identify TP53 mutations associated with worse outcomes, indicating potential for enhanced clinical management.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Wei Zhang, Emma Li, Lily Wang, Brian D. D. Lehmann, X. Steven Chen
Summary: This study aimed to identify genes associated with neoadjuvant chemotherapy (NAC) response and disease-free survival (DFS) of triple-negative breast cancer (TNBC) patients. Large-scale meta-analyses were conducted to identify genes associated with NAC response and survival outcomes. The integration and division of gene associations provided insights into potential NAC response mechanisms and biomarker discovery.
Article
Oncology
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice Andre, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai
Summary: This study compared the response to neoadjuvant chemotherapy and survival between patients with triple-negative breast cancer (TNBC) and non-TNBC. The results showed that TNBC patients had higher pathologic complete response rates but lower 3-year progression-free survival rates and 3-year overall survival rates. TNBC was associated with increased risk for visceral metastases, lower risk for bone recurrence, and shorter postrecurrence survival. Patients with TNBC had worse survival if they had residual disease after neoadjuvant chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Clinton Yam, Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Gheath Alatrash, Haven Garber, Lei Huo, Fei Yang, Anne Philips, Qing-Qing Ding, Bora Lim, Naoto T. Ueno, Kasthuri Kannan, Xiangjie Sun, Baohua Sun, Edwin Roger Parra Cuentas, William Fraser Symmans, Jason B. White, Elizabeth Ravenberg, Sahil Seth, Jennifer L. Guerriero, Gaiane M. Rauch, Senthil Damodaran, Jennifer K. Litton, Jennifer A. Wargo, Gabriel N. Hortobagyi, Andrew Futreal, Ignacio I. Wistuba, Ryan Sun, Stacy L. Moulder, Elizabeth A. Mittendorf
Summary: The study found that in patients with triple-negative breast cancer receiving neoadjuvant therapy, TCR clonality, PD-L1 positivity, CD3(+):CD68(+) ratio, and spatial proximity of T cells to tumor cells were associated with pathologic complete response. Deep immune profiling through detailed phenotypic characterization and spatial analysis can improve prediction of pathologic complete response in these patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Roberto A. Leon-Ferre, Tina J. Hieken, Judy C. Boughey
Summary: Neoadjuvant chemotherapy has become the preferred approach for most HER2-positive and triple-negative breast cancers, with initial motivations being to decrease surgical extent and advance drug development, recent trials have shown survival advantages from escalating systemic treatment in patients with residual disease.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Lili Yang, Yuya Haga, Akihide Nishimura, Yuki Tsujii, Suzuno Tanahashi, Hirofumi Tsujino, Kazuma Higashisaka, Yasuo Tsutsumi
Summary: Among TNBC subtypes, the BL2 subtype has the lowest survival rate and highest risk of metastasis after chemotherapy treatment. Alpha B-crystallin (CRYAB) is highly expressed in BL2 subtypes and is associated with brain metastasis in TNBC patients. We hypothesized that alpha B-crystallin is associated with increased cell motility in the BL2 subtype after chemotherapy.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Fengzhu Guo, Jialu Ma, Cong Li, Shuning Liu, Weizheng Wu, Chunxiao Li, Jiani Wang, Jinsong Wang, Zhijun Li, Jingtong Zhai, Fangzhou Sun, Yantong Zhou, Changyuan Guo, Haili Qian, Binghe Xu
Summary: This study investigated the role of PRR15 in triple-negative breast cancer (TNBC) and its clinical applications. The expression of PRR15 was found to be different between TNBC and non-TNBC patients, and its down-regulation promoted malignant progression in TNBC through the PI3K/Akt signaling pathway. Decreased PRR15 expression in TNBC was associated with more aggressive clinicopathological characteristics, enhanced metastasis, and poor disease-free survival. These findings suggest that PRR15 could serve as a promising indicator of disease outcomes in TNBC.
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Jhih-Kai Pan, Cheng-Han Lin, Yao-Lung Kuo, Luo-Ping Ger, Hui-Chuan Cheng, Yun-Chin Yao, Michael Hsiao, Pei-Jung Lu
Summary: The study identified high levels of miR-211 as a prognostic marker for breast cancer brain metastasis, enhancing trans-blood-brain barrier migration and adherence of tumor cells leading to brain colonization and poor survival outcomes. Furthermore, downstream targets of miR-211, SOX11 and NGN2, play a role in regulating TNBC brain metastasis.
Editorial Material
Oncology
Priyanka Sharma
Summary: Pathologic response is an important tool for optimizing the escalation and deescalation of adjuvant treatment. Neoadjuvant carboplatin-taxane combination shows promise as a chemotherapy deescalation strategy for triple-negative breast cancer. However, several key points, including trial design/patient selection, response biomarkers, role of immunotherapy, and patient advocate input, need to be carefully considered for the advancement of neoadjuvant chemotherapy deescalation investigations.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Ravi Medikonda, Siddhartha Srivastava, Timothy Kim, Yuanxuan Xia, Jennifer Kim, Christopher Jackson, Jon Weingart, Debraj Mukherjee, Chetan Bettegowda, Gary Gallia, Henry Brem, Kristin Redmond, Vered Stearns, Lawrence Kleinberg, Michael Lim
Summary: The study found that triple negative breast cancer (TNBC) patients have a higher burden of intracranial disease and a higher rate of new brain metastasis formation compared to non-TNBC patients. Additionally, whole brain radiation therapy (WBRT) does not provide a survival benefit for TNBC patients.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Oncology
S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J. U. Blohmer, J. Furlanetto, D. M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P. A. Fasching, V. Nekljudova, C. Denkert, M. Untch
Summary: Adding durvalumab to neoadjuvant chemotherapy in patients with TNBC significantly improved survival rates, despite a modest increase in pCR, and without a durvalumab adjuvant component.
ANNALS OF ONCOLOGY
(2022)
Review
Nanoscience & Nanotechnology
Siyan Liu, Jing Li, Lin Gu, Kunzhe Wu, Hua Xing
Summary: Chemoimmunotherapy shows promise for treating TNBC, but challenges remain in improving efficacy and reducing side effects.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Genetics & Heredity
Justine Marsolier, Pacome Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Lea Baudre, Kevin Grosselin, Mylene Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouze, Anne-Vincent Salomon, Elisabetta Marangoni, Leila Perie, Celine Vallot
Summary: The persistence of drug-resistant cancer cells is a major clinical challenge, particularly in triple-negative breast cancer. This study reveals that the repressive histone mark H3K27me3 plays a crucial role in regulating cell fate and chemotherapy tolerance in cancer cells. Manipulating H3K27me3 levels effectively enhances the potential of cancer cells to tolerate chemotherapy and delays tumor recurrence. These findings underscore the importance of understanding chromatin landscapes in shaping cancer cell response to initial therapy.
Review
Pharmacology & Pharmacy
Hao Tian, Dandan Ma, Xuanni Tan, Wenting Yan, Xiujuan Wu, Cheng He, Ling Zhong, Yan Zhang, Bingjie Yu, Yi Zhang, Xiaowei Qi
Summary: Platinum derivatives and taxanes have demonstrated efficacy in treating TNBC, with their combination leading to reduced systemic toxicity and improved outcomes in both neoadjuvant and adjuvant settings. The sensitivity of BRCA1-mutated cells to taxanes remains a challenge, but recent evidence supports the benefit of combining carboplatin and paclitaxel for better pathological complete response in TNBC patients. Various clinical studies are ongoing to further explore the mechanisms and advantages of platinum and taxane-based chemotherapies in early TNBC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
John Nikitas, Todd DeWees, Sana Rehman, Chris Abraham, Jeff Bradley, Cliff Robinson, Michael Roach
CLINICAL LUNG CANCER
(2019)
Article
Oncology
Michael C. Roach, Tarita O. Thomas, Anthony J. Paravati, Anita Mahajan
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Article
Oncology
Soumon Rudra, Naomi Jiang, Stephen A. Rosenberg, Jeffrey R. Olsen, Michael C. Roach, Leping Wan, Lorraine Portelance, Eric A. Mellon, Anna Bruynzeel, Frank Lagerwaard, Michael F. Bassetti, Parag J. Parikh, Percy P. Lee
Article
Oncology
James Kavanaugh, Geoffrey Hugo, Cliff G. Robinson, Michael C. Roach
SEMINARS IN RADIATION ONCOLOGY
(2019)
Article
Oncology
William R. Kennedy, Prashant Gabani, John Nikitas, Clifford G. Robinson, Jeffrey D. Bradley, Michael C. Roach
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
William R. Kennedy, Michael C. Roach, Maria A. Thomas, Laura Ochoa, Michael B. Altman, Leonel F. Hernandez-Aya, Amy E. Cyr, Julie A. Margenthaler, Imran Zoberi
PRACTICAL RADIATION ONCOLOGY
(2020)
Article
Oncology
Comron Hassanzadeh, Michael Roach, Keith Rich, Patty Karraker, Clifford Robinson, Jeff Michalski, Stephanie Perkins, Jiayi Huang, Christina Tsien, Christopher Abraham
PRACTICAL RADIATION ONCOLOGY
(2020)
Article
Oncology
William R. Kennedy, Pamela P. Samson, Prashant Gabani, John Nikitas, Jeffrey D. Bradley, Michael C. Roach, Clifford G. Robinson
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
John Nikitas, Michael Roach, Cliff Robinson, Jeffrey Bradley, Jiayi Huang, Stephanie Perkins, Christina Tsien, Christopher Abraham
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2020)
Article
Oncology
Lauren E. Henke, Jeffrey R. Olsen, Jessika A. Contreras, Austen Curcuru, Todd A. DeWees, Olga L. Green, Jeff Michalski, Sasa Mutic, Michael C. Roach, Jeffrey D. Bradley, Parag J. Parikh, Rojano Kashani, Clifford G. Robinson
ADVANCES IN RADIATION ONCOLOGY
(2019)
Article
Oncology
William R. Kennedy, Prashant Gabani, John Nikitas, Pamela P. Samson, Clifford G. Robinson, Jeffrey D. Bradley, Michael C. Roach
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2019)
Review
Oncology
Alexander J. Lin, Michael Roach, Jeffrey Bradley, Clifford Robinson
TRANSLATIONAL LUNG CANCER RESEARCH
(2019)
Article
Oncology
Todd A. DeWees, John Nikitas, Sana Rehman, Jeffrey D. Bradley, Cliff G. Robinson, Michael C. Roach
PRACTICAL RADIATION ONCOLOGY
(2019)
Article
Oncology
Pamela Samson, Sana Rehman, Aditya Juloori, Todd DeWees, Michael Roach, Jeffrey Bradley, Gregory M. M. Videtic, Kevin Stephans, Clifford Robinson
PRACTICAL RADIATION ONCOLOGY
(2018)